Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7848303 | 0.98 | ADRA2A (0.45) | ADRA2AADRA2BADRA2CLOXL2MAPT | |
| SCHEMBL31340065 | 0.82 | ADRA2A (0.46) | ADRA2AADRA2BADRA2CLOXL2MAPT | |
| SCHEMBL31340046 | 0.82 | ADRA2A (0.46) | ADRA2AADRA2BADRA2CLOXL2MAPT | |
| SCHEMBL3973866 | 0.79 | ADRA2A (0.46) | ADRA2AADRA2BADRA2CMAPTSLC2A1 | |
| SCHEMBL21596159 | 0.78 | AGTR1 (0.39) | ADRA2AADRA2BADRA2CMAPTSLC2A1 | |
| Ammonia Solution, Strong SCHEMBL7429890 | 0.78 | ADRA2A (0.45) | ADRA2AADRA2BADRA2CMAPTSLC2A1 | |
| SCHEMBL29559792 | 0.77 | LOXL2 (0.37) | ADRA2AADRA2BADRA2CLOXL2MAPT | |
| SCHEMBL7100559 | 0.75 | ADRA2A (0.43) | ADRA2AADRA2BADRA2CMAPTSLC2A1 | |
| SCHEMBL21962089 | 0.75 | KMT2A (0.45) | ADRA2AADRA2BADRA2CMAPTSLC2A1 | |
| SCHEMBL11815139 | 0.75 | HSPB1 (0.45) | ADRA2AADRA2BADRA2CMAPTSLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190351-A1 | Benzoimidazole Derivatives and Glycogen Synthase Kinase-3 Beta Inhibitors Containing the Same | ONCOTHERAPY SCIENCE, INC. (JP) | 2011-08-04 | — | — | US | disclosed |
| EP-2309855-A1 | BENZOIMIDAZOLE DERIVATIVES AND GLYCOGEN SYNTHASE KINASE-3 BETA INHIBITORS CONTAINING THE SAME | Oncotherapy Science, Inc. (JP) | 2011-04-20 | — | — | EP | disclosed |
| US-7659284-B2 | Inhibitors of ATP-protein kinase; 7-(3-chloro-4-fluoro-phenylamino)-2-(4-pyrrolidin-1-ylmethyl-phenylamino)-thiazolo[4,5-b]pyridine-6-carbonitrile | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-09 | — | — | US | disclosed |
| WO-2010014794-A1 | BENZOIMIDAZOLE DERIVATIVES AND GLYCOGEN SYNTHASE KINASE-3 BETA INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2010-02-04 | — | — | WO | disclosed |
| CN-100506801-C | Inhibitors of glycogen synthase kinase 3 | CHIRON CORP (US) | 2009-07-01 | — | — | CN | disclosed |
| US-7547702-B2 | 4-amino-quinazolines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-7425557-B2 | Inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| EP-1789055-A2 | THIAZOLOPYRIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-30 | — | — | EP | disclosed |
| US-7045519-B2 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-05-16 | — | — | US | disclosed |
| US-7037918-B2 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1317433-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2003-06-11 | — | — | EP | disclosed |
| US-6489344-B1 | FOR TREATMENT DIABETES IN A HUMAN OR ANIMAL SUBJECT | CHIRON CORPORATION | 2002-12-03 | — | — | US | disclosed |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2002-10-24 | — | — | US | disclosed |
| WO-2002024667-A1 | 4-AMINO-QUINAZOLINES | MERCK PATENT GMBH (DE) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002020495-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
| CN-1312807-A | Inhibitors of glycogen synthase kinase 3 | CHIRON CORP (US) | 2001-09-12 | — | — | CN | disclosed |
| EP-1087963-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | Chiron Corporation (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065897-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 1999-12-23 | — | — | WO | disclosed |
| WO-1998003485-A1 | PHENOXYPROPANOLAMINES HAVING β3-ADRENERGIC ANTAGONIST ACTIVITY | SANOFI (FR) | 1998-01-29 | — | — | WO | disclosed |
| US-5274089-A | A estra-1,3,5(10)-triene derivative | THE UPJOHN COMPANY (US) | 1993-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190351-A1 | Benzoimidazole Derivatives and Glycogen Synthase Kinase-3 Beta Inhibitors Containing the Same | GSK3B, GSK3A, GYS2 | ADRA2A 4079/4885ADRA2B 3312/4885ADRA2C 3289/4885 |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | ADRA2A 3769/4885ADRA2B 3485/4885ADRA2C 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.